Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 |
---|---|---|---|---|
Income Statement | ||||
Total Revenue | 2.01B | 1.90B | 1.84B | 1.72B |
Gross Profit | 600.18M | 527.98M | 439.38M | 408.19M |
EBITDA | 376.12M | 368.26M | 360.15M | 330.20M |
Net Income | 149.32M | 166.54M | 179.95M | 166.73M |
Balance Sheet | ||||
Total Assets | 2.84B | 2.52B | 2.49B | 2.30B |
Cash, Cash Equivalents and Short-Term Investments | 73.87M | 183.25M | 31.37M | 37.66M |
Total Debt | 527.64M | 1.95B | 905.00M | 1.04B |
Total Liabilities | 2.47B | 2.22B | 1.16B | 1.30B |
Stockholders Equity | 342.64M | 275.67M | 1.16B | 973.32M |
Cash Flow | ||||
Free Cash Flow | 186.91M | 210.35M | 164.98M | 228.35M |
Operating Cash Flow | 259.70M | 274.68M | 234.32M | 274.34M |
Investing Cash Flow | -407.91M | -71.27M | -75.31M | -50.93M |
Financing Cash Flow | 171.41M | -51.53M | -165.29M | -216.68M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | $22.47B | 29.81 | 9.27% | 1.04% | 7.98% | 72.22% | |
73 Outperform | $3.43B | 66.27 | 1.76% | ― | 0.76% | ― | |
69 Neutral | $2.93B | 19.60 | 18.79% | 0.82% | ― | ― | |
65 Neutral | €4.07B | 17.15 | -2.44% | 3.85% | 1.88% | -16.39% | |
46 Neutral | $59.20M | ― | 84.03% | ― | -13.83% | 87.09% |
On August 7, 2025, Concentra Group Holdings Parent, Inc. announced its financial results for the second quarter ending June 30, 2025, reporting a 15.2% increase in revenue to $550.8 million compared to the previous year. The company also declared a cash dividend of $0.0625 per share and raised its financial guidance for the fiscal year 2025, reflecting strong growth in patient visits and operational efficiencies from recent acquisitions, positioning it for continued momentum.
The most recent analyst rating on (CON) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Concentra Group Holdings Parent, Inc. stock, see the CON Stock Forecast page.
On June 26, 2025, Concentra Group Holdings Parent, Inc. announced the appointment of Vipin Gopal and Brigid Bonner to its Board of Directors, effective July 1, 2025. This strategic move is aimed at enhancing the company’s growth and shareholder value by leveraging the new directors’ expertise in data, technology, and business transformation. Vipin Gopal brings extensive experience in data and AI strategy from roles at major companies like Eli Lilly and Walgreens Boots Alliance, while Brigid Bonner offers a wealth of knowledge in strategic planning and digital transformation from her leadership roles in various sectors. The appointments are expected to strengthen Concentra’s position in the healthcare industry as it navigates technological advancements and complex market dynamics.
The most recent analyst rating on (CON) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Concentra Group Holdings Parent, Inc. stock, see the CON Stock Forecast page.
On June 1, 2025, Concentra Health Services, a subsidiary of Concentra Group Holdings Parent, Inc., completed the acquisition of Onsite Innovations for $55 million. This acquisition doubles the size of Concentra’s Onsite Health segment and aligns with its growth strategy, expanding its reach to approximately 350 onsite health clinics across over 40 states. The integration aims to enhance service offerings and maintain high-quality care, with key leaders from Onsite Innovations joining Concentra to ensure business continuity and growth.
The most recent analyst rating on (CON) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Concentra Group Holdings Parent, Inc. stock, see the CON Stock Forecast page.